{"id":"repaglinide-and-metformin-combination-tablet","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Repaglinide works by closing potassium channels in the beta cells of the pancreas, leading to insulin release. Metformin, on the other hand, decreases glucose production in the liver by inhibiting gluconeogenesis and increases insulin sensitivity by reducing glucose uptake in the liver and increasing glucose uptake in muscles.","oneSentence":"Repaglinide stimulates insulin secretion from the pancreas, while metformin decreases glucose production in the liver and increases insulin sensitivity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:52.230Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT02616666","phase":"PHASE4","title":"A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2016-08-25","conditions":"Type 2 Diabetes Mellitus","enrollment":632},{"nctId":"NCT05236530","phase":"PHASE1","title":"Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and Dolutegravir","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-03-09","conditions":"Malaria","enrollment":48},{"nctId":"NCT03359837","phase":"PHASE4","title":"Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-01-20","conditions":"Type 2 Diabetes Mellitus","enrollment":384},{"nctId":"NCT04141163","phase":"PHASE1, PHASE2","title":"Metformin in Patients With Fragile X","status":"UNKNOWN","sponsor":"Rowan University","startDate":"2019-10-29","conditions":"Fragile X Syndrome","enrollment":40},{"nctId":"NCT01709305","phase":"PHASE4","title":"A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-11-08","conditions":"Type 2 Diabetes Mellitus","enrollment":5570},{"nctId":"NCT01489644","phase":"PHASE1","title":"Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-06","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":62},{"nctId":"NCT00399711","phase":"PHASE3","title":"Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":560},{"nctId":"NCT01490658","phase":"PHASE1","title":"Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-06","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":93},{"nctId":"NCT00959101","phase":"PHASE1","title":"Comparison of Repaglinide and Metformin Combination Tablet Versus Repaglinide and Metformin as Separate Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-08","conditions":"Diabetes, Healthy","enrollment":42},{"nctId":"NCT01780051","phase":"PHASE1","title":"A Pharmacokinetic Study to Compare Co-administration of Repaglinide and Metformin HCl to Administration of Combination Preparation of Those Two Components","status":"COMPLETED","sponsor":"Dalim BioTech Co., Ltd.","startDate":"2013-03","conditions":"Diabetes Mellitus, Type 2","enrollment":48},{"nctId":"NCT00118963","phase":"PHASE4","title":"Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes","status":"COMPLETED","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2003-01","conditions":"Diabetes Mellitus, Type 2","enrollment":102}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"repaglinide and metformin combination tablet","genericName":"repaglinide and metformin combination tablet","companyName":"Novo Nordisk A/S","companyId":"novo-nordisk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Repaglinide stimulates insulin secretion from the pancreas, while metformin decreases glucose production in the liver and increases insulin sensitivity. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}